Nanotechnology-based drug delivery for the treatment of CNS disorders

Mittal, KR; Pharasi, N; Sarna, B; Singh, M; Rachana,; Haider, S; Singh, SK; Dua, K; Jha, SK; Dey, A; Ojha, S; Mani, S; Jha, NK

Nanotechnology-based drug delivery for the treatment of CNS disorders

Mittal, KR Pharasi, N Sarna, B Singh, M Rachana, Haider, S Singh, SK Dua, K

Jha, SK Dey, A Ojha, S Mani, S Jha, NK

Permalink

Publisher:: Walter de Gruyter GmbH
Publication Type:: Journal Article
Citation:: Translational Neuroscience, 2022, 13, (1), pp. 527-546
Issue Date:: 2022-12-31

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (990.89 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Mittal, KR
dc.contributor.author	Pharasi, N
dc.contributor.author	Sarna, B
dc.contributor.author	Singh, M
dc.contributor.author	Rachana,
dc.contributor.author	Haider, S
dc.contributor.author	Singh, SK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Jha, SK
dc.contributor.author	Dey, A
dc.contributor.author	Ojha, S
dc.contributor.author	Mani, S
dc.contributor.author	Jha, NK
dc.date.accessioned	2023-01-28T21:27:52Z
dc.date.available	2023-01-28T21:27:52Z
dc.date.issued	2022-12-31
dc.identifier.citation	Translational Neuroscience, 2022, 13, (1), pp. 527-546
dc.identifier.issn	2081-6936
dc.identifier.uri	http://hdl.handle.net/10453/165552
dc.description.abstract	<jats:title>Abstract</jats:title> <jats:p>Approximately 6.8 million people die annually because of problems related to the central nervous system (CNS), and out of them, approximately 1 million people are affected by neurodegenerative diseases that include Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s disease. CNS problems are a primary concern because of the complexity of the brain. There are various drugs available to treat CNS disorders and overcome problems with toxicity, specificity, and delivery. Barriers like the blood–brain barrier (BBB) are a challenge, as they do not allow therapeutic drugs to cross and reach their target. Researchers have been searching for ways to allow drugs to pass through the BBB and reach the target sites. These problems highlight the need of nanotechnology to alter or manipulate various processes at the cellular level to achieve the desired attributes. Due to their nanosize, nanoparticles are able to pass through the BBB and are an effective alternative to drug administration and other approaches. Nanotechnology has the potential to improve treatment and diagnostic techniques for CNS disorders and facilitate effective drug transfer. With the aid of nanoengineering, drugs could be modified to perform functions like transference across the BBB, altering signaling pathways, targeting specific cells, effective gene transfer, and promoting regeneration and preservation of nerve cells. The involvement of a nanocarrier framework inside the delivery of several neurotherapeutic agents used in the treatment of neurological diseases is reviewed in this study.</jats:p>
dc.language	en
dc.publisher	Walter de Gruyter GmbH
dc.relation.ispartof	Translational Neuroscience
dc.relation.isbasedon	10.1515/tnsci-2022-0258
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1109 Neurosciences
dc.title	Nanotechnology-based drug delivery for the treatment of CNS disorders
dc.type	Journal Article
utslib.citation.volume	13
utslib.for	1107 Immunology
utslib.for	1109 Neurosciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	open_access	*
dc.date.updated	2023-01-28T21:27:39Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	13
utslib.citation.issue	1

Abstract:

Abstract Approximately 6.8 million people die annually because of problems related to the central nervous system (CNS), and out of them, approximately 1 million people are affected by neurodegenerative diseases that include Alzheimer’s disease, multiple sclerosis, epilepsy, and Parkinson’s disease. CNS problems are a primary concern because of the complexity of the brain. There are various drugs available to treat CNS disorders and overcome problems with toxicity, specificity, and delivery. Barriers like the blood–brain barrier (BBB) are a challenge, as they do not allow therapeutic drugs to cross and reach their target. Researchers have been searching for ways to allow drugs to pass through the BBB and reach the target sites. These problems highlight the need of nanotechnology to alter or manipulate various processes at the cellular level to achieve the desired attributes. Due to their nanosize, nanoparticles are able to pass through the BBB and are an effective alternative to drug administration and other approaches. Nanotechnology has the potential to improve treatment and diagnostic techniques for CNS disorders and facilitate effective drug transfer. With the aid of nanoengineering, drugs could be modified to perform functions like transference across the BBB, altering signaling pathways, targeting specific cells, effective gene transfer, and promoting regeneration and preservation of nerve cells. The involvement of a nanocarrier framework inside the delivery of several neurotherapeutic agents used in the treatment of neurological diseases is reviewed in this study.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165552